Risk factors

Instil Bio (TIL) risk factors

Item 1A of every Instil Bio, Inc. 10-K on file, and what changed from one year to the next.

Open TIL in Gloomberb →
  • FY2025 10-K risk factors

    74 risks, 16 new, 23 dropped, 30 reworded since the prior year. Instil Bio shifted from clinical-stage oncology to an acquirer of early-stage assets after discontinuing multiple programs and workforce reductions.

    Filed Mar 27, 2026
  • FY2024 10-K risk factors

    81 risks. Instil Bio faces high financial losses, having accumulated $655.1 million in deficit as of December 31, 2024. The company relies heavily on its collaboration with ImmuneOnco for its lead product candidates AXN-2510/IMM2510 and AXN-27M/IMM27M. It has zero commercial products and no history of completing clinical trials.

    Filed Mar 04, 2025